Dermata Therapeutics (DRMA) investor relations material

Company overview and business model

• Pivoting from pharmaceutical development to consumer skincare, leveraging clinical dermatology experience and Bioneedle technology for professional-grade at-home treatments.

• Tome Foundational Treatment launched Aug. 25, 2026; sold through the brand website as one-time purchases or discounted monthly subscriptions.

• Bioneedle uses wild-harvested, minimally processed freshwater sponge; the weekly mask is mixed with a fluidizing agent for at-home application.

• Plans professional and clinic distribution alongside direct-to-consumer sales; Tome Clearing Treatment, using salicylic acid and Bioneedle for acne, is targeted for launch in 2027.

• Processed raw-material inventory is considered sufficient for current Foundational Treatment sales and the planned Clearing Treatment launch under current operating assumptions.

Financial performance and metrics

• Audited FY2025 and FY2024 financial statements carry an unqualified audit opinion with an explanatory paragraph on going-concern uncertainty.

• Forward-looking risk disclosures anticipate significant operating losses for the foreseeable future and a need for additional capital.

Use of proceeds and capital allocation

• Resale proceeds go to selling stockholders; cash proceeds from warrant exercises, if any, are intended for working capital and general corporate purposes.

• Registration expenses are paid by the issuer; estimated issuance and distribution expenses total $61,000.